These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37088527)

  • 1. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
    Zhou JX; Torres VE
    Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E; Rodas L; Blasco M; Molina A; Quintana L
    Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Residence Time Peptide Antagonist for the Vasopressin V
    Xiong X; Wang N; Zhang Y; Zhao W; Pang N; Fu K; Zhou N; Zhou X; Guo D
    J Med Chem; 2024 Apr; 67(7):5935-5944. PubMed ID: 38509003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ADPKD treatment: Tolvaptan and Octreotide].
    Galliani M; Chicca S; Vitaliano E; Moscaritolo E; Calvaruso L; Iorio F; Paone A
    G Ital Nefrol; 2019 Dec; 36(6):. PubMed ID: 31830392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
    Devuyst O; Torres VE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression.
    Quiroga B; Torra R
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
    Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
    Torres VE
    Nephrol Dial Transplant; 2019 Jan; 34(1):30-34. PubMed ID: 30312438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug repurposing in autosomal dominant polycystic kidney disease.
    Zhou JX; Torres VE
    Kidney Int; 2023 May; 103(5):859-871. PubMed ID: 36870435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice.
    Hines CB; Hooper GL; Collins-Yoder A
    Nephrol Nurs J; 2020; 47(2):145-150. PubMed ID: 32343088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.
    Reif GA; Yamaguchi T; Nivens E; Fujiki H; Pinto CS; Wallace DP
    Am J Physiol Renal Physiol; 2011 Nov; 301(5):F1005-13. PubMed ID: 21816754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.